3-{2,6,8-trioxo-9-[(2S,3S,4R)-2,3,4,5-tetrahydroxypentyl]-1,2,3,6,8,9-hexahydro-7H-purin-7-Yl}propyl dihydrogen phosphate

DB02290ExperimentalSmall molecule

3-{2,6,8-trioxo-9-[(2S,3S,4R)-2,3,4,5-tetrahydroxypentyl]-1,2,3,6,8,9-hexahydro-7H-purin-7-Yl}propyl dihydrogen phosphate: Overview.

Formula / weight: C₁₃H₂₁N₄O₁₁P · 440.2998 g/mol (avg)

Resolves to

Compound

ChEMBLCHEMBL477508PubChem657025

Structure

InChIKeyKPHFGOGGKPGLTM-OOZYFLPDSA-NSMILES[H]N1C2=C(N(CCCOP(O)(O)=O)C(=O)N2C[C@H](O)[C@H](O)[C@H](O)CO)C(=O)N([H])C1=O

Targets

P9WHE9ribH

What you can answer from here — as of August 31, 2026

1Protein targetEach mapped to UniProt, with action and pharmacological action

Listed above

2+ReferencesStructured and connected to the statements they support

Which drugs share a target with 3-{2,6,8-trioxo-9-[(2S,3S,4R)-2,3,4,5-tetrahydroxypentyl]-1,2,3,6,8,9-hexahydro-7H-purin-7-Yl}propyl dihydrogen phosphate, and which of those have an active Phase 3 trial?

Answer this in Biopharma OS Sign in to your account

Create a free account or log in to explore the full data card.

Create Account